Trial Information

Summary: EXTEND (Eltrombopag eXTENded Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, with Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study

You have been asked to participate in this research study because you have chronic idiopathic thrombocytopenic purpura (ITP) (persistent low blood platelets), and you have previously taken part in a study with the experimental drug eltrombopag olamine (SB-497115-GR).  The purpose of this study is to see if eltrombopag is safe and effective when used to treat people with ITP.  Another purpose is to determine if the study drug will reduce or eliminate the need to use other ITP medications.  This study is intended to continue until eltrombopag is approved for long-term use in subjects with ITP, by the Food and Drug Administration (FDA).  Your participation in this study will continue for as long as you continue to benefit from the study treatment and do not experience greater than moderate side effects associated with the study medication.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: December 1, 2008 at 3:15:46 PM